hers compounded semaglutide safety Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle Hims & Hers Plan to

Of those receiving GLP-1s, nearly all (97.5%) were receiving semaglutide

A 2023 register-based study by Tang and colleagues followed 88,000 older adults with type 2 diabetes for 10 years and observed a 30% lower risk of dementia compared to those taking sulfonylureas

Mochi Healths Public Response In its own public statement, Mochi Health framed the lawsuit as part of a broader pattern of large pharmaceutical companies challenging smaller, more affordable healthcare alternatives

In this comprehensive article, we will explore what GLP-1 is, how it was discovered, where it is produced in the body, its effects and half-life, and why it has become the most promising target in pharmaceutical weight loss

Dry mouth is not a typical side effect but may occur due to gastrointestinal symptoms

A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)